This article is more than 5 years old. Information may no longer be current.

AMO sales up almost 25% in 2005

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA ANA, Calif. — Advanced Medical Optics reported net sales for 2005 of $920.7 million, a 24% increase over 2004 levels. The company attributed the gain primarily to its acquisition of VISX, which was completed in May.

Overall, AMO reported a net loss of $453 million in 2005, compared with a net loss of $129 million in 2004. AMO attributed the losses to charges related to acquisitions and recapitalizations, the company said in a press release.

For the year, total cataract/implant sales rose 23% to $496 million. Total IOL sales grew 10% to $259 million during 2004, mainly because of increased sales of Tecnis and the accelerated phase out of older-generation silicone and PMMA IOLs, according to the company. The Tecnis Multifocal, ReZoom and Verisyse lenses accounted for $22.9 million in sales.

Sales of AMO’s viscoelastics grew 77% during 2005, reaching $131 million; AMO attributed the growth to the integration of the Healon (sodium hyaluronate) line of viscoelastics.

Phacoemulsification sales rose 7.5% in 2005 to $81 million, and the company noted “strong sales” of its Sovereign phacoemulsifier with WhiteStar technology.

Laser vision correction sales totaled $123 million in 2005, with system sales accounting for $27 million. The increase in sales was also attributed to the VISX acquisition.

Eye care sales declined 8.5%, to $301 million in 2004. AMO blamed soft performance in Japan and its acceleratied rationalization of non-strategic products for the decline.